As RSV cases start to rise this season, AstraZeneca and Sanofi have struggled to match the demand for their new monoclonal antibody to protect against RSV — and several Democrat senators are asking the two companies to explain what’s causing the supply holdup.
The FDA in…
Click here to view original post
